SCHEDULE: PAVmed Boosts Lucid Diagnostics Stake to 28.3%
Beneficial Ownership Update
PAVmed Inc. has increased its beneficial ownership in Lucid Diagnostics Inc. to 28.3% through recent stock awards and voting agreements, solidifying its influence as the parent company.
Summary
- PAVmed Inc. (Reporting Person) beneficially owns 38,816,903 shares of Lucid Diagnostics Inc. (Issuer) Common Stock, representing 28.3% of the class.
- PAVmed holds sole voting power over all 38,816,903 shares and sole dispositive power over 31,302,444 shares.
- On February 20, 2025, Lucid Diagnostics granted restricted stock awards of 300,000 shares each to officers Dr. Aklog, Mr. McGrath, Mr. O'Neil, and Mr. Gordon, vesting May 30, 2028.
- On February 20, 2025, Lucid Diagnostics granted restricted stock awards of 112,800 shares each to directors Mr. Sparks and Ms. White, vesting May 30, 2028.
- On September 25, 2025, a trust controlled by Mr. Glennon purchased 129,000 shares in open market transactions at approximately $1.04 per share, totaling $133,782.70.
- PAVmed, as the parent company, has significant influence over director elections and other matters due to its ownership stake and voting agreements.
- PAVmed entered into a new voting agreement on October 9, 2025, granting it proxy over 3,177,500 Common Stock votes and 3,862,911 other capital stock votes from a stockholder.
- Previous voting agreements with officers cover 4,336,959 Common Stock votes.
- Key executives and directors of PAVmed also hold significant positions at Lucid Diagnostics, including Chairman/CEO, CFO, COO, and General Counsel.
Sentiment
Score: 7
Explanation: The filing indicates a strengthening of PAVmed's control and alignment of management interests through stock awards and voting agreements, which can be viewed positively for stability and strategic direction. Insider buying also suggests confidence. However, it's primarily a disclosure of ownership changes rather than operational performance, so the sentiment is moderately positive due to increased control and insider confidence.
Positives
- Increased beneficial ownership and voting control by PAVmed Inc. in Lucid Diagnostics Inc., potentially indicating strong commitment and strategic alignment.
- Open market purchase by a trust controlled by a PAVmed Principal (Mr. Glennon) at $1.04 per share, showing insider confidence.
- Granting of restricted stock awards to key officers and directors of Lucid Diagnostics, aligning their interests with long-term company performance.
Risks
- The concentration of voting power in PAVmed Inc. (28.3% of Common Stock and an estimated 27.2% of all capital stock) could limit the influence of other shareholders on corporate decisions.
- The existence of various agreements (Debt Exchange Agreement, Security and Pledge Agreement, MSA, PBERA, Issuer Note SPA) creates complex interdependencies and obligations between PAVmed and Lucid, which could pose operational or financial risks if not managed effectively.
- Restricted stock awards to officers and directors are subject to vesting, and their value is tied to future stock performance, which carries inherent market risk.
Future Outlook
PAVmed Inc. intends to continuously review its ownership of Lucid Diagnostics Inc. and may acquire or sell additional securities based on an ongoing evaluation of Lucid's business, financial condition, operations, prospects, market conditions, and alternative investment opportunities. No present intention to acquire or sell securities beyond what is described in the filing.
Industry Context
This filing reflects a common dynamic in the medical technology and diagnostics sector where a parent company maintains significant control and strategic oversight over its subsidiary. The granting of restricted stock awards and open market purchases by insiders are typical mechanisms to align management and director interests with long-term company performance, particularly in growth-oriented sectors like medical diagnostics.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Voting Control | PAVmed Inc. entered into a new voting agreement on October 9, 2025, with a Lucid Diagnostics stockholder, granting PAVmed proxy over 3,177,500 Common Stock votes and 3,862,911 other capital stock votes. This enhances PAVmed's ability to influence shareholder votes. | 2025-10-09 | Significantly increases PAVmed's control over corporate decisions, including director elections, potentially consolidating power and reducing influence of other shareholders. |
| Management/Director Compensation | Lucid Diagnostics granted restricted stock awards to its officers (Dr. Aklog, Mr. McGrath, Mr. O'Neil, Mr. Gordon) and directors (Mr. Sparks, Ms. White) on February 20, 2025, vesting on May 30, 2028. | 2025-02-20 | Aligns the long-term interests of key management and directors with shareholder value through equity incentives, subject to vesting conditions. |
| Shareholder Lockup | Certain Principals (Dr. Aklog, Mr. McGrath, Mr. O'Neil, Mr. Gordon, Mr. Sparks, Ms. White) entered into 45-day lockup agreements on September 10, 2025, following an underwritten offering of Common Stock by Lucid Diagnostics. | 2025-09-10 | Temporarily restricts the sale of shares by key insiders, which can provide market stability post-offering but also limits their liquidity. |
Related Party Transactions
- PAVmed Inc. is the parent company of Lucid Diagnostics Inc.
- Several executive officers and directors hold dual roles at both PAVmed and Lucid Diagnostics (e.g., Dr. Aklog as Chairman/CEO of both).
- Lucid Diagnostics granted restricted stock awards to officers and directors who are also Principals of PAVmed.
- PAVmed has various agreements with Lucid Diagnostics, including a Management Services Agreement (MSA) and a Payroll and Benefit Expense Reimbursement Agreement (PBERA).
- PAVmed has voting obligations in connection with Lucid's convertible notes sale (Issuer Note SPA).
Stakeholder Impact
- Shareholders: PAVmed's increased voting control may reduce the influence of minority shareholders. The restricted stock awards and insider purchases could be seen as positive signals of management confidence.
- Management/Directors: Restricted stock awards align their interests with long-term company performance. Lockup agreements temporarily restrict their ability to sell shares.
- Creditors: The Debt Exchange Agreement and Security and Pledge Agreement indicate ongoing financial arrangements that could impact creditors.
Next Steps
- PAVmed Inc. will continue to review its ownership of Lucid Diagnostics Inc.
- PAVmed or its Principals may acquire additional securities or sell existing holdings in the future, dependent on various market and company-specific factors.
- Restricted stock awards granted to officers and directors will vest on May 30, 2028, subject to acceleration in certain circumstances.
- Lockup agreements for certain Principals related to the September 10, 2025, offering will restrict transfers for 45 days.
Key Dates
| Date | Description |
|---|---|
| 2018-05-12 | Initial date of the Management Services Agreement (MSA) between PAVmed and Lucid Diagnostics. |
| 2022-04-04 | Date of the Security and Pledge Agreement between PAVmed and a holder of its convertible notes. |
| 2022-11-30 | Date of the Payroll and Benefit Expense Reimbursement Agreement (PBERA) between PAVmed and Lucid Diagnostics. |
| 2022-12-02 | Date of Amendment No. 1 to the Schedule 13D. |
| 2024-02-02 | Date of Amendment No. 2 to the Schedule 13D. |
| 2024-02-20 | Date of Amendment No. 3 to the Schedule 13D. |
| 2024-11-12 | Date of the Securities Purchase Agreement (Issuer Note SPA) for convertible notes issued by Lucid Diagnostics. |
| 2024-11-15 | Date of the Debt Exchange Agreement between PAVmed and a holder of its convertible notes. |
| 2024-12-12 | Date of Amendment No. 4 to the Schedule 13D. |
| 2025-02-20 | Lucid Diagnostics granted restricted stock awards to officers and directors. |
| 2025-03-24 | Date of Lucid Diagnostics' Annual Report on Form 10-K, which describes the MSA and PBERA. |
| 2025-05-12 | Date of the most recent amendment to the Management Services Agreement (MSA). |
| 2025-05-30 | Vesting date for restricted stock awards granted on February 20, 2025. |
| 2025-09-10 | Date of an underwritten offering of Common Stock by Lucid Diagnostics, leading to lockup agreements. |
| 2025-09-25 | A trust controlled by Mr. Glennon purchased 129,000 shares of Common Stock in open market transactions. |
| 2025-10-09 | Date of the new Voting Agreement between PAVmed and a Lucid Diagnostics stockholder. |
| 2025-10-10 | Filing date of this Amendment No. 5 to Schedule 13D. |
Recommendation
holdThe filing primarily details changes in beneficial ownership and corporate governance arrangements, solidifying PAVmed's control over Lucid Diagnostics. While insider purchases and restricted stock awards suggest confidence and alignment of interests, the filing does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The increased control by the parent company could be viewed as a stabilizing factor, but without further financial insights, a 'hold' position is prudent for a seasoned investor.
Keywords
PAVmed Inc., Lucid Diagnostics Inc., Schedule 13D/A, Beneficial Ownership, Common Stock, Voting Proxy, Restricted Stock Awards, Insider Trading, Corporate Governance, Medical Technology, Diagnostics, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.